Get Ready for the Fall

Recs

1

Disney Buys Marvel!

David Gardner called it. He’s up 1,334%! See what David’s recommending that you buy NEXT.

"The bigger they are, the harder they fall." It's the worst nightmare of every investor in today's market -- buying a hot stock just before it takes a nosedive.

Every day, MSN Money publishes a list of stocks whose shares have just hit new 52-week highs. And every day, investors read the list and tremble -- some with greed, others with terror. In our Motley Fool CAPS investing community, these top stocks usually enjoy favorable ratings, because everyone loves a winner. But what should you do when some of CAPS' smartest investors pan one of these hot stocks?

For starters, consider using the "52 week high" list as a starting point for further research. Stocks can rise for many reasons, but a little help from Motley Fool CAPS can make it easier to figure out how worthy those reasons are. Let's see what the more than 115,000 stock gurus (and counting) in CAPS have to say about the list's latest contenders:

 

One Year Ago Today

Recent Price

CAPS Rating

(5 max):

Orbital Sciences  (NYSE: ORB)

$21.58

$27.89

****

Marsh & McLennan  (NYSE: MMC)

$26.45

$26.45

****

CV Therapeutics (Nasdaq: CVTX)

$10.23

$11.03

****

Amgen (Nasdaq: AMGN)

$50.08

$65.06

****

Parlux Fragrances  (Nasdaq: PARL)

$3.36

$6.49

*

Five stars = highest possible CAPS rating; one star = lowest. Companies are selected from the "New 52-Week Highs" list published on MSN Money on the Saturday following close of trading last week. One-year-ago and recent prices provided by Yahoo! Finance. CAPS ratings from Motley Fool CAPS.

Everybody loves a winner
When stocks soar on the wings of success, bears become rare. So it's no surprise to find this week's list largely infused with high-quality, four-star stocks (three of which are, in fact, Motley Fool newsletter recommendations.) What is surprising is that we're also catching a whiff of something more lowbrow. Is someone here wearing "Paris Hilton"?

Indeed someone is: Parlux Fragrances, which manufactures the perfume. Without further explanation, let's move right on to examining ...

The bear case against Parlux Fragrances

  • NetscribeConsGds introduced us to Parlux early last year: "Parlux Fragrances is engaged in the creation, design, manufacture, distribution and sale of prestige fragrances and beauty related products, marketed primarily through specialty stores, national department stores and perfumeries on a worldwide basis." (Including, to no one's surprise, both Bon-Ton and J.C. Penney -- while Nordstrom (NYSE: JWN) and Saks (NYSE: SKS) apparently took a pass.) "The company holds licenses to manufacture and distribute watches, cosmetics and handbags, purses and other small leather goods, and sunglasses as well as to manufacture and sell fragrances."
  • AW2580 managed to state the bear case on this one early last year in six words flat: "No cash flow, too much debt."
  • And CAPS All-Star TheGreatSatan dispatches Parlux with six more: "Parlux will launch Queen Latifah fragrance."

Ouch. But there's no need to resort to ad hominems (homina? hominae?), TheGreatSatan. Parlux's numbers tell us all we need to know about this company. That its P/E is 540. That its sales growth seems to be slowing during the past few years. That growth is projected at 15% per year long-term ... but there's just one analyst projecting this.

None of which is encouraging -- and all of which suggests this 52-week-high-hitter could be ready for its fall.

Time to chime in
Of course, the aim of this column isn't just to tell you what I think about Parlux Fragrances -- or even what other CAPS members are saying. We really want to hear your thoughts. Click on over to CAPS and tell us what you think.

Motley Fool CAPS : It's fun, it's free, and it just might make you famous.

“The Next Great Investment”… That’s how a top global investor describes India’s potential. On Nov. 28, The Motley Fool’s Tim Hanson returns to India to prove it. Follow along in real time and get his TOP pick first (Hanson returned from China in July with a stock that’s up 169%!). Enter email below.

Fool contributor Rich Smith does not own shares of any company named above. You can find him on CAPS, publicly pontificating under the handle TMFDitty, where he's currently ranked No. 394 out of more than 115,000 players. Marsh & McLennan is a Motley Fool Inside Value selection. Orbital Sciences and CV Therapeutics are Rule Breakers recommendations. The Fool has a disclosure policy.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On August 27, 2008, at 6:02 PM, rafalta wrote:

    Parl has improved this year and its perfumes are selling better.Needs reevaluation from pundits.

Add your comment.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 709200, ~/Articles/ArticleHandler.aspx, 11/24/2009 3:04:57 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

The Must-Read Story on Fool.com
Live Chat on India, China, and the Demise of the Dollar

Related Tickers

11/24/2009 2:48 PM
MMC $22.83 Up +0.14 +0.62%
Marsh & McLennan C… CAPS Rating: ***
ORB $12.85 Down -0.17 -1.31%
Orbital Sciences C… CAPS Rating: *****
AMGN $56.60 Up +0.35 +0.62%
Amgen, Inc. CAPS Rating: ****
JWN $33.77 Down -0.22 -0.65%
Nordstrom, Inc. CAPS Rating: **
SKS $6.48 Down -0.02 -0.31%
Saks, Inc. CAPS Rating: **
PARL $2.18 Down -0.02 -0.91%
Parlux Fragrances,… CAPS Rating: *
CVTX $20.01 Down +0.00 +0.00%
CV Therapeutics, I… CAPS Rating: **

Community: Investing Wiki

Term Of The Hour

Barriers to entry: Barriers to entry are aspects of a business that inhibit a competitor's efforts to offer equivalent products or services.

Want to learn more or edit this definition?
Click here to read more!